Sign up to save your podcasts
Or
Share Addressing Unmet Needs in Metastatic Uveal Melanoma
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Addressing Unmet Needs in Metastatic Uveal Melanoma
CME credits: 1.00
Valid until: 05-01-2027
Claim your CME credit at https://reachmd.com/programs/cme/addressing-unmet-needs-in-metastatic-uveal-melanoma/48980/
Dive into what sets metastatic uveal melanoma (mUM) apart from cutaneous melanoma and why that matters for clinical decision-making. Explore how HLA A*02:01 typing informs patient selection and how bispecific TCR therapy is changing the treatment landscape. Real-world cases and clinical trial data bring these concepts to life, with special attention to application in VA and academic settings. Whether you're a medical oncologist, ocular oncologist, ophthalmologist, or APP, this discussion is designed to sharpen your skills and your care aligned with the latest science.
=
View all episodes
By ReachMD
4.3
33 ratings
CME credits: 1.00
Valid until: 05-01-2027
Claim your CME credit at https://reachmd.com/programs/cme/addressing-unmet-needs-in-metastatic-uveal-melanoma/48980/
Dive into what sets metastatic uveal melanoma (mUM) apart from cutaneous melanoma and why that matters for clinical decision-making. Explore how HLA A*02:01 typing informs patient selection and how bispecific TCR therapy is changing the treatment landscape. Real-world cases and clinical trial data bring these concepts to life, with special attention to application in VA and academic settings. Whether you're a medical oncologist, ocular oncologist, ophthalmologist, or APP, this discussion is designed to sharpen your skills and your care aligned with the latest science.
=